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Allogeneic bone marrow transplantation has become an
accepted form of treatment both for aplastic anaemia and
acute leukaemia and of course for immune deficiencies
where it was first successfully applied. However, the m a m
indication reraains aplastic anaemia and leukaemia and the
results over the last few years have not changed much.
About half of the patients will recover, the treat-
ment will be for them successful and about half of them
will die. This IS not only unfortunate for the patients
but perhaps even more frustrating is that we still do not
know which patients will die and which will survive. We
do know that the graft versus host disease and mterstitial
pneumoma are the m a m cause of death but we are as yet un-
able to identify the factors which mitiate these compli-
cations. The fact that monozygotic twins have far less of
these complications mdicate that lmmunogenetics play a
role. Identifymg that role is further complicated by the
fact that non-immunogenetic factors such as age, the sex
difference between donor and recipient, the rate of lrra-
diation play a role as well. - -
Three topics will be discussed here: 1. presensiti-
zation and supportive care; 2. mcompatibility for non-
MHC factors detected by anto-bodies; 3. mcompatibility for
non-MHC factors dfetected by _cellular typing.
The first topic concerns the problem of supportive
care. Supportive care is extremely important for several
reasons but especial]y so because lf supportive care is
optimal, it is not always necessary to perform a bone mar-
row transplantafc'on
Figure 1 shows four groups of patients suffermg from
from aplastic anaemia, a part of which has been given a
bone marrow transplant after pretreatment with cyclophos-
phamide. The other patients, also suffermg from aplastic
anaemia, have been treated by ALG alone or ALG and bone
marrow and their graft survival is as good as that of the
transplanted patients. There are several studies both m
Europe and in the States which support this and it can be
said that half of the patients suffermg from aplastic
anaemia will improve significantly and become mdependent
of transfusion lf given ALG but this is only possible lf
one has optimal supportive care.
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And here we are confronted with the problem of immuniza-
tion. Of course prevention of immunization is best and this
is possible if one is careful not to transfuse any lympho-
cytes. Red cells can be given after filtering them through
cotton wool filters which will retain all lymphocytes and
such red cells will not immunize the patient. The remaining
Problems are then the platelet transfusions which often
contain a substantial number of lymphocytes. Simply
through one extra second centrifugation one can remove these
lymphocytes and in that way sensitization of the patient
becomes far less of a problem.
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•Figure -i'. Comparison of the incidence of refractoriness ~~i
after platelet transfusion in 28 patients who received
Standard platelet transfusions (Group A) and 68 patients
who received leukocyte-free platelet transfusions (Group
B). Numbers under the lines indicate patients at risk.
(Eernisse & Brand 1981)
The results of a study performed by Eernisse and
Brand are shown in figure 2. (1) Patients who received
platelet transfusions which are lymphocyte-free through
one Single extra centrifugation remain for -ι-he larger part
non-refractory, not only after three months but after a
much longer period of time as well.
So the first lesson is that in supportive care, pre-
vention is best and that one should try to keep the patient
clean, that is that no HLA-antibody formation should be
induced and this is possible by giving red cells and
platelets which are lymphocyte-free. However, what to do
if the patient becomes immunized. Of course one can give
compatible platelets, but there is another possibility,
which, although still experimental, is of sufficient in-
terest to be mentioned here. Sabbe et al. (2) described
that in patients with leukocyte antibodies who received
ATG for the treatment of aplastic anaemia, the leukocyte
antibodies disappeared while other antibodies reraained
unchanged. Figure 3 shows a patient who received ATG on
day 0. At that time he had strong leukocyte antibodies
which reacted with almost 100% of the panel. After about
one month time, the leukocyte antibodies had disappeared
and remaxned very low even although he received many blood
and platelet transfusions. These however were free from
lymphocytes. It is remarkable that there is hardly any
fall in titer of antibodies against Rubella and Mumps
and the total immunoglobulm level remains more or less
normal.
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fFigure 3. Evolution of total IgG content and specific —j
antibodies to allogeneic lymphocytes and two endemic
viruses after therapy with ATG. (Sabbe et al. 1981)
We have observed this in three other patients and this
led to a randomized prospective study which was performed
by Claas et al. from our group. Mice were first immunized
so that they had formed leukocyte antibodies and then they
were given ATG. In the animals that received ATG the anti-
bodies had disappeared after 45 days and in the control
a significant amount of antibodies had remained. The raecha-
nism of ATG suppression of antibody formation is as yet
unclear. It might well be that anti-thymocyte globulin con-
tains a large number of anti-idiotypic antibodies and that
these anti-idiotypic antibodies are able to either kill
the plasma cell while it secretes the leukocyte antibodies,
or stop plasma cells in another way from making such anti-
bodies .
Let us next have a look at the non-MHC factors as
they can be detected by antibodies. These are especially
important with aplastic anaemia patients because these re-
ceive so many transfusions. Antibodies will be formed not
only against HLA but also against granulocytesfc specific,
plateletsuspecific and many other antigens. HLA antibodies
as a rule can be considered to be no problem if an HLA
identical sibling bone marrow donor is available and can
be used. But the Situation is different for the non-MHC
factors. In the earlier days of bone marrow transplanta-
tion, and especially in the treatment of aplastic anaemia,
rejection was still a problem. This has nowadays been over-
come by more effective pretransplant conditioning regimes
and it is rarely more seen. However, in the earlier days
rejection was a problem, and in a combined study with the
group of Seattle, we found a significant correlation be-
tween the presence of monocyte antibodies and. .rejection
(3). Recently thejse data have been confirmed by Gluckmann
et al. (4) . They^-performed a systematic study to see
whether there was a correlation between the occurrence of
GVH, and monocyte antibodies, but such a correlation could
not be found. Although monocyte antibodies against non-MHC
loci might have played a role in the past by inducing bone
marrow rejection, today they do not seem to be very impor-
tant.
Still, we should not forget the possibility that this
all might be due to the lack of adequate Information. Our
knowledge of the immunogenetics of the monocyte antigens
is really very limited. We do know that several loci are
involved which code for these determinants and data from
Moraes and Stastny (5) xndicate that some of these loci
might go along with the MHC and that other loci lie out-
side the MHC region. As the number of the loci and the num-
ber of alleles are unknown typing for these antigens is not
yet possible and thus ma^chinq is not possible as well·,. Un-
less we will be able to do so", we~feälly do' not knöw "\r~ )
, " •
whether incompatibilities for these monocyte Systems might
play a role in GVH.
The 1ast topic concerns the question whether typing
donor-recipient pairs with cytotoxic lymphocytes could be
helpful in preventing graft versus host disease. Now CTL
typing can be performed in two ways, one of these is by
using allo-CTL's. Such alle- CTL' s have been extremely use-
ful in picking up biochemical variants of ®&4φφ& HLA anti-
gens which sofar have not been detected by serology. Unre-
lated individuals are selected which differ for only one
antigen, for instance A2 and in the Standard CML assay A2
specific CTL's can be induced. ^Van der Poel (6) from our
group typed about 60 people with 4 different A2 specific
CTL's and figure 4 shows that one can easily differentiate
between the positive results, above 60% relative killing
and those which were negative, generally under 30%.
PERCENT RELATIVE CYTOTOXIC RESPONSES
OF HLA-A2 SPECIFIC CTL'S
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-'Figure 4. Percent relative cytotoxic responses of HLA-A2
specific CTL's. Open circles represent HLA-A2 positive tar-
get cells, closed circles represent HLA-A2 negative target
cells. The black triangles indicate people which typed se-
rologically A2 positive but fail to react or reacted very
weakly with the CTL's. The outlier HLA-A2 positive target
cells LV1-LV5 are numbered 1,2,3,4 and 5 respectively.
Further studies in which these cells were used as stimula-
tors and responders have indicated that there are at least
two variants and very recent bxochemical data collected to-
gether with Ploegh (manuscrxpt in preparation) has confirm-
ed that they are variants very much like the M7 variant
described by Biddison (7). These allo CTL's, however, will
not be very useful in bone marrow transplantation for the
simple reason that although they are indeed able to recog-
nize variants m class I antigens, such variants segregate
with HLA haplotypes and for that reason HLA xdentical sib-
,lings will always be xdentxcal for the variants
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_[The situa-
rTTxön~~i-s"^ Hxfferent wxth what we wxll call the auto CTL's
whxch are really nothxng more than the well known Doherty-
Zinkernagel phenomenon (8).
In patients sufferxng from aplastic anaemia, Goulmy
et al. (9) found cytotoxxc lymphocytes which were MHC res-
tricted and directed agaxnst H-Y. The first case, Mrs. Re,
concerned a woman who suffered from aplastic anaemia and
who received a large number of blood and platelet trans-
fusions and then xt was found that her lymphocytes were
able to kxll the lymphocytes of her brother. Α further stu-
dy showed that the cells of thxs woman killed all A2 posi-
txve male cells and vxrtually none of the female A2 posi-
txve cells; A2 negative cells were not killed at all.
Thxs was a typxcal example of an anti-H-Y/A2 restrict-
ed cytotoxxc lymphocyte, and Goulmy (10) has found since
then several other examples and other workers found them
as well (11,12). Here we wxll refer to such MHC restricted
CTL cells as auto CTL's because Mrs. Re her" ce-11 was A2
posxtxve but she kxlled A2 posxtxve targets on the condi-
tion that they carried also the non-MHC determinant H-Y.
What we call here auto CTL*s, react with class I antigens
and H-Y and for that reason-»do not always segregate with
HLA. Of course xf you study a famxly xn whxch all the chil-
dren are males, CTL wxll segregate wxth the HLA haplotypes.
Althougn these fxndxngs have been confirmed, it is
uncertam to which extent they are really of clinxcal im-
portance. 1t xs a fact however that female donors lead
more often to complxcatxons than male donors. However xn
such patients a clear correlatxon with the presence of MHC
restricted HY CTL's has not been found although it should
not be forgotten that perhaps they have not been looked for
hard enough, or with the wrong kind of techniques. The
climcal importace of these auto-A2 restricted anti-HY CTL's
remains thus open.
Although the climcal importance of the auto or MHC
restricted CTL's which are directed against the HY deter-
jminants is still,apart from statistical grounds, unclear,
this raight be different for a newly detected non-MHC deter-
minant. Recently a patient (designated HA) was transplanted
because of acute myeloid leukaeraia and received a bone mar-
row transplant from an HLA identical sister. Their HLA type
was A2, B2 7, Bw6 2, Cwl, Cw3, DR1, DR4, MLC and CML were nega-
tive and there was a good take. Then a severe taetrchronic
graft versus host disease set in. Goulmy et al. (13)
studied this patient by usmg his cells after transplanta-
tion as responder cells. Table 1 shows that when posttrans-
plant effector cells of the patients are taken, the cells
of the patient pretransplantation were strongly lysed.
After transplantation they were not and the bone marrow
donor was also not lysed, so the conclusion is that the
bone marrow donor saw something on the patient's cells which
was absent from her cells. The cells recognized a polymor-
phism in unrelated individuals.
TABLE 1. Percentage lysis obtaineu with posttransplant
effector cells of patient riA.
target cells % lysis
patient HA (pretransplant) + 59
patient HA (posttransplant) - 1
bone marrow donor - 3
unrelated mdividual Α + 5
unrelated individual Β - 7
unrelated individual C +26
unrelated individual D + 3 5
(Goulmy et al. 1982)
Next the family of the patient was studied (figure 5).
Both parents were killed by the CTL's of the patient taken
posttransplantation. The patient before transplantation
was positive, the donor negative, and of the three haplo-
identical, two were killed and one was not." So- m this
one family we have two examples m which HLA identical
siblmgs were di f f erejtjnj using CTL typmg. To test the spe-
cificity of the CTL a large panel of over 100 people has
been typed and table 2 shows a part of the results. There
was a clear correlation with A2. All A2 positive cells were
killed on the condition that they were not a variant, the 5
negatives were the variants as discussed earlier. The only
two cells which were to the best of our knowledge no
variants and rfere not killed/were the bone marrow donor
and the haploidentical sister. But the lymphocytes of the
patient contained also CTL's which segregated with a split
of B2 7 and Bw6 2.
We think that we are here confronted with a Situation
which is very similar to that of HY with a number of lmpor-
tant differenccs. In the first place this mmor HA antigen,
the recognition of which is restricted by either HLA-A2,B27,
or Bw62 might have a very high frequency, at least as far
TÄ2 positxve people are concerned.
Percen t l y s i s i n family HA
ab
CML : +91%
02
cd
CML : +84%
04 03
patient donor
ad ad ac ac ac
+82% -3% +85% +92% +6%
(Goulmy et al 1982)
Figure 5.
TABLE 2. Analysis of HLA restrxcted anti-mmor HA antigen
lysis .
HLA serotypmg of target cells
HLA-A2 B2 7 Bw62 Others
+ 3 8 2 7 0
C M L •
5 44
(Goulmy et al. J982)
Whether thxp mmor antigen is- localised on the 6th chromo-
some we do not know. If lt is on chromosome 6, lt is loca-
lxsed on the Α sxde as has been shown by crossover families.
lt xs yet unknown whether the clones whxch are restrxcted
to B27 and Bw62 are dxrected agaxnst the same HA antxgen as
the A2 restrxcted clone, but xt seems to be the most lxkely
explanatxon. Usxng such cells we wxll type retrospectxvely
all our bone marrow donors and recxpxents whxch are avaxl-
able and whxch are e:ther A2,B27 and Bw62 posxtxve to see
whether there xs a correlatxon wxth graft versus host
dxsease and dxscrepancxes, xncompatxbxlxtxes, for thxs
rtu nor HA antxgen.
These studxes show that both auto CTL's and allo CTL's
react wxth part of an HLA class I antagen. Allo CTL's do
but auto CTL's do not always segregate wxth HLA and for
[that reason the auto CTL's are more interesting to use in
the study for borte marrow transplantation. Typing with *
auto CTL's might provide insight in the pathogenesis of GVH
disease and in any case they will give us further insight
in the immunogenetics.
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Fig. 1. Percent relative cytotoxic responses of HLA-A2 specific CTLs.
Open circles represent HLA-A2 positive target cells. Closed
circles represent HLA-A2 negative target cells. The outlier
HLA-A2 positive target cells LV1-LV5 are numbered 1, 2, 3, 4 and
5 respectiveLy.
HLA phenotypes of LV1 to LV5:
LV1: AI A2 B8 Bw50 - Bw6 Cwb Cw7 DR3 DR6
LV2: A2 Aw29 Β7 Bw38 Bw4 Bw6 - - DRw6 -
LV3: A2 A26 B2 7 B37 Bw4 - Cw2 Cw6
LV4: A2 A3 B8 Bwi3 - Bw6 Cw4 -
LV5: Λ2 Aw32 Bw^4 Bw50 Bw4 Bw6 Cw6 - DR 1 DR7
